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Heterozygosity for the CCR5 Δ32 allele is associated with delayed progression to AIDS in human immunodeficiency virus type 1 (HIV-1)
infection. Here we describe an unusual HIV-1 isolate from the blood of an asymptomatic individual who was heterozygous for the CCR5 Δ32
allele and had reduced levels of CCR5 expression. The primary virus used CCR5, CXCR4, and an unusually broad range of alternative
coreceptors to enter transfected cells. However, only CXCR4 and CCR5 were used to enter primary T cells and monocyte-derived macrophages,
respectively. Full-length Env clones had an unusually long V1/V2 region and rare amino acid variants in the V3 and C4 regions. Mutagenesis
studies and structural models suggested that Y308, D321, and to a lesser extent K442 and E444, contribute to the broad coreceptor usage of these
Envs, whereas I317 is likely to be a compensatory change. Furthermore, database analysis suggests that covariation can occur at positions 308/317
and 308/321 in vivo. Y308 and D321 reduced dependence on the extracellular loop 2 (ECL2) region of CCR5, while these residues along with
Y330, K442, and E444 enhanced dependence on the CCR5 N-terminus compared to clade B consensus residues at these positions. These results
suggest that expanded coreceptor usage of HIV-1 can occur in some individuals without rapid progression to AIDS as a consequence of changes in
the V3 region that reduce dependence on the ECL2 region of CCR5 by enhancing interactions with conserved structural elements in G-protein-
coupled receptors.
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Human immunodeficiency virus type 1 (HIV-1) enters cells
via interaction of the viral envelope glycoproteins (Env) with
CD4 and a coreceptor. Macrophage (M)-tropic HIV-1 viruses
primarily use CCR5 (R5) as a coreceptor, whereas T cell line-
164 P.R. Gorry et al. / Virology 362 (2007) 163–178tropic HIV-1 viruses use CXCR4 (X4) (Berger et al., 1999;
Doms and Trono, 2000; Moore et al., 2004). Dual-tropic viruses
(R5X4) use both coreceptors. A subset of viruses can also use
alternative coreceptors including CCR3, CCR2b, CCR8, Apj,
Strl33 (BONZO/CXCR6), Gpr1, Gpr15 (BOB), CX3CR1,
ChemR23, or RDC1 for entry (Berger et al., 1999; Doms and
Trono, 2000; Moore et al., 2004). However, usage of core-
ceptors other than CCR5 and CXCR4 by primary viruses in
vitro is rare (Zhang et al., 1998), and infection of primary cells
occurs, with few exceptions, exclusively via CCR5 or CXCR4
(Cilliers et al., 2005; Moore et al., 2004). R5 strains pre-
dominate during primary infection and the asymptomatic phase,
whereas expansion of viral coreceptor usage and emergence of
X4 or R5X4 strains is frequently associated with rapid disease
progression.
Delayed or slow HIV-1 disease progression can be defined
by the lack of development of an AIDS defining illness for at
least 10 years after infection with a slowly declining CD4+ T
cell count. Viral genetic factors associated with slow
progression or nonprogression include mutations in the HIV-
1 gag, rev, vif, vpr, vpu, env and nef genes (Churchill et al.,
2004, 2006; Deacon et al., 1995; Kirchhoff et al., 1995;
Michael et al., 1997; Shioda et al., 1997; Wang et al., 2000).
Host genetic factors linked to a delay in the onset of AIDS and
prolonged survival include the CCR5 Δ32 mutation, CCR2b-
V64I polymorphism, and certain HLA haplotypes (Dean et al.,
1996; Eugen-Olsen et al., 1997; Huang et al., 1996; Smith et
al., 1997) (reviewed in O'Brien and Moore, 2000; Roger,
1998). The CCR5 Δ32 mutation, which results in a 32-
nucleotide deletion, is common in Caucasians, with heterozy-
gosity in 15 to 20% and homozygosity in 1%. Individuals
homozygous for the CCR5 Δ32 allele are highly resistant to
HIV-1 transmission (O'Brien and Moore, 2000), whereas
heterozygotes are susceptible but typically have delayed CD4+
T cell decline and prolonged survival compared to CCR5 wt/wt
individuals (Dean et al., 1996; Eugen-Olsen et al., 1997;
Huang et al., 1996; Michael et al., 1997). Among CCR5 Δ32/
wt heterozygotes, there is large variation in levels of CCR5
expression (Cohen et al., 1997; de Roda Husman et al., 1999).
Slow progression of HIV-1 disease has been correlated with
reduced levels of CCR5 expression on CD4+ T lymphocytes and
monocytes compared to levels in CCR5 wt/wt individuals
(Cohen et al., 1997; de Roda Husman et al., 1999). Nonetheless,
there is considerable overlap between CCR5 expression levels in
CCR5 Δ32/wt heterozygotes and individuals with the CCR5
wt/wt genotype (de Roda Husman et al., 1999).
In this study, we isolated and characterized HIV-1 from the
blood of an asymptomatic individual who was heterozygous for
the CCR5 Δ32 allele and had reduced levels of CCR5 cell
surface expression. In addition to using CCR5 and CXCR4, the
virus has highly expanded utilization of alternative coreceptors
that is broader than that of any previously described HIV-1
virus. Mutagenesis studies and structural models suggested
Y308 and D321 in the V3 region of gp120, and to a lesser extent
K442 and E444 in the C4 region, contribute to the broad
coreceptor usage of Envs cloned from the viral isolate. Fur-
thermore, studies using mutant CCR5 coreceptors indicated thatY308, D321, Y330, K442, and E444 alter dependence on the N-
terminal and extracellular loop 2 (ECL2) regions of CCR5. The
results suggest that expanded coreceptor usage of HIV-1 can
occur in some individuals without rapid progression to AIDS as
a consequence of changes in the V3 region that enhance
interactions with conserved structural elements in G-protein-
coupled receptors (GPCRs).
Results
Clinical history and isolation of HIV-1
The subject is a homosexual male who was infected with
HIV-1 via sexual contact and first tested seropositive for HIV-1
in May 1989. As of 2006, the subject remained asymptomatic
with no AIDS defining illness. His antiretroviral therapy (ART),
plasma HIV-1 RNA levels, and CD4 counts are summarized in
Supplementary Table 3. The subject was seropositive for cyto-
megalovirus, hepatitis A, hepatitis C, and Toxoplasma gondii.
Genetic analysis of CCR5 alleles by PCR demonstrated hetero-
zygosity for the CCR5 Δ32 deletion (data not shown). Two-
color FACS staining of peripheral blood mononuclear cells
(PBMC) collected in October 2003 demonstrated that the mean
percentage of CCR5+ cells in the CD4+ T lymphocyte fraction
was 0.9% (n=2, SD=0.08) as compared with 19.3% in healthy
HIV-1-negative control subjects (n=7, SD=10.15). HIV-1 was
isolated from PBMC collected in August 2000 by coculture
with CD8-depleted donor PBMC as described (Gorry et al.,
2001). Attempts to isolate HIV-1 from cryopreserved PBMC
collected in October 1998 and March 1999 were unsuccessful.
Coreceptor usage
The ability of the primary virus isolate to utilize CCR5,
CXCR4, or alternative coreceptors for virus entry was first
determined in canine Cf2-Luc cells (Gorry et al., 2001) (Fig.
1A). The X4 NL4-3, R5 ADA, and R5X4 89.6 HIV-1 viruses
were used as positive controls (Gorry et al., 2001, 2002b). The
primary virus used both CCR5 and CXCR4 for virus entry.
Efficient usage of CCR2b, CCR3, CCR8, Gpr1, Gpr15, Strl33
and Apj was also demonstrated. Compared to 89.6, usage of
CCR2b, Gpr1, and Apj by the primary virus was approximately
5-, 20- and 2-fold greater, respectively. Compared to ADA,
usage of CCR8, Gpr15 and Strl33 by the primary virus was
approximately 5-, 6- and 2-fold greater. The virus could also
enter canine Cf2-Luc cells transfected with CD4 alone, albeit at
low levels. Coreceptor usage in human U87 astrocytoma cells
was similar to that in Cf2-Luc cells with the exception that virus
entry was not detected in U87 cells transfected with CD4 alone
(data not shown), suggesting that entry in Cf2-Luc cells
expressing CD4 alone was mediated by an endogenous canine
coreceptor. The promiscuous pattern of coreceptor usage
resembles that of some SIV and HIV-2 virus strains (Edinger
et al., 1998; Morner et al., 1999; Reeves et al., 1997, 1999;
Rucker et al., 1997), which can infect certain cell types lacking
CD4. However, virus entry mediated by CCR3, CCR5,
CXCR4, or the endogenous coreceptor expressed on Cf2-Luc
Fig. 1. Coreceptor usage. (A) Cf2-Luc cells were transfected with pcDNA3-CD4 alone or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR2b, CCR3,
CCR5, CCR8, CXCR4, Gpr1, Gpr15, Strl33 or Apj and infected with equivalent amounts of each control HIV-1 virus (left panel) or patient-derived virus (right panel).
Control cells were transfected with pcDNA3 plasmid only. Mock-infected cells were treated with culture medium. Cell lysates were prepared at 48 h post-infection and
assayed for luciferase activity. (B) Cf2-Luc cells transfected with pcDNA3-CD4 alone or cotransfected with pcDNA3-CD4 and plasmids expressing CCR5, CX3CR1,
RDC1, CCR7, CXCR1, CXCR2, CXCR3, C5aRC9, D2DRsC9, DARC, D6 or FMLP-R were infected with equivalent amounts of each HIV-1 virus. HIV-1 entry was
measured as above. Data are represented as means from duplicate infections. Error bars represent standard deviations. Similar results were obtained in two independent
experiments.
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tested whether the primary virus could utilize other GPCRs as
coreceptors. Virus entry was detected in Cf2-Luc cells
coexpressing CD4 and the promiscuous CC-chemokine recep-
tor D6 (Nibbs et al., 1997), but not in cells coexpressing CD4
and CX3CR1, Rdc1, CCR7, CXCR1, CXCR2, CXCR3,
complement 5a anaphylatoxin receptor (C5aRC9), dopamine
receptor 2-short form (D2DrsC9), duffy antigen/receptor for
chemokines (DARC), or formyl-methionine–leucine–phenyl-
alanine receptor (FMLP-R) (Fig. 1B). Cell surface expression of
these GPCRs was readily detected (M. Farzan and H. Choe,
unpublished observations). Preincubation with zidovudine
(AZT) abolished infection (data not shown). The broad and
efficient usage of alternative coreceptors by the patient virus
was unique by comparison to over 50 other primary HIV-1
viruses analyzed in similar assays (Gorry et al., 2001, 2002b;
Gray et al., 2005; Lawson et al., 2004; Solomon et al., 2005 and
data not shown). Thus, the patient virus demonstrates unusually
broad and efficient usage of alternative coreceptors compared to
other HIV-1 strains.
Replication kinetics
We examined the capacity of the primary virus to replicate in
PBMC, CEMx174 cells, and monocyte-derived macrophages
(MDM) (Fig. 2A). The ADA and NL4-3 viruses were used as
positive controls for replication in PBMC; NL4-3 was used as a
positive control for replication in CEMx174 cells; ADA, the R5YU2 strain, and the X4 NDK strain (Ancuta et al., 2001; Gorry
et al., 2001) were used as positive controls for replication in
MDM. In PBMC, the primary virus replicated to low levels
compared to NL4-3 and ADA, reaching peak levels of repli-
cation at day 10 post-infection compared to days 4 and 7 for
NL4-3 and ADA, respectively. In CEMx174 cells, the primary
virus reached peak levels of virus replication at day 24 post-
infection compared to day 7 for NL4-3. In MDM, the primary
virus replicated at low levels compared to ADA, YU2 and
NDK. These results, together with experiments showing that the
same primary virus stock had similar infectivity on Cf2-Luc
cells coexpressing CD4 and CCR5 or CXCR4 compared to the
control viruses (Fig. 1), suggest that the primary virus has
reduced replication capacity in PBMC, CEMx174, and MDM
compared to several laboratory and primary HIV-1 strains.
Sensitivity to CCR5 and CXCR4 inhibitors
The efficient usage of alternative coreceptors in transfected
cells raised the possibility that infection of primary CD4+ cells
by the primary virus might be mediated by alternative
coreceptors. Therefore, sensitivity to small molecule inhibitors
of CCR5 or CXCR4 (TAK-779 and AMD3100, respectively)
was tested in PBMC and MDM. We first determined sensitivity
to AMD3100 and TAK-779 in PBMC at a range of concentra-
tions previously shown to be effective at inhibiting infection by
other primary HIV-1 viruses (Gorry et al., 2002a). AMD3100 or
AMD3100 and TAK-779 in combination abolished infection of
Fig. 2. Replication kinetics and sensitivity to coreceptor inhibitors and antibody neutralization. (A) PBMC, CEMx174 cells and MDM were infected with equivalent
amounts of each HIV-1 virus, as described in Materials and methods, and cultured for 28 days. Virus production in culture supernatants was measured by RT assays.
(B) PBMC were treated with concentrations of CCR5 (TAK-779) or CXCR4 inhibitors (AMD3100), or both inhibitors increasing 10-fold from 0.01 to 100 μM, and
infected with the patient virus in the presence of each concentration of inhibitor. Virus production in culture supernatants at day 14 post-infection was measured by
quantitation of soluble HIV-1 p24 Ag. Production of p24 Ag was calculated as a percentage of the amount produced in the absence of inhibitors, and then expressed as
the percentage of inhibition relative to cultures containing no inhibitor. (C) MDM were treated with TAK-779 (100 nM), AMD3100 (1.2 μM) or both for 1 h prior to
infection. Untreated cells contained no inhibitor. Cells were infected with equivalent amounts of HIV-1 NDK or the patient isolate and cultured for 21 days in the
presence of each inhibitor. HIV-1 production in culture supernatants was measured by RT assays. (D) Virus stocks were treated with concentrations of MAbs or CD4-
IgG2 increasing 10-fold from 0.01 to 100 μM for 30 min, and used to infect PBMC. Virus production in culture supernatants and calculation of percent neutralization
was determined as per panel (B). Values shown are means from duplicate infections. Error bars represent standard deviations (A, C). Results are representative of two
independent experiments using cells obtained from different donors.
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779 alone had only a modest inhibitory effect (Fig. 2B). Similar
results were obtained at days 7 and 10 post-infection (data not
shown). The 50% inhibitory concentration (IC50) and IC90 of
AMD3100 at day 14 post-infection was 0.65 μM and 5.5 μM,
respectively, whereas the IC50 and IC90 of TAK-779 at day 14
was 58 μM and>100 μM, respectively. PBMC from a donor
homozygous for the CCR5 Δ32 allele supported replication
of the primary virus, which was completely abolished by
AMD3100 (data not shown). These results demonstrate that the
virus primarily uses CXCR4 for infection of PBMC. We then
determined sensitivity to AMD3100 and TAK-779 in MDM at
concentrations previously shown to completely inhibit infection
of MDM or microglia (Gorry et al., 2001; Simmons et al., 1998)
(Fig. 2C). AMD3100 abolished infection of MDM by NDK, buthad no inhibitory effect on the primary virus. TAK-779
abolished infection of MDM by the primary virus, but had no
inhibitory effect on NDK. AMD3100 and TAK-779 in com-
bination abolished infection of MDM by either virus. These
results demonstrate exclusive use of CCR5 for infection of
MDM. Thus, despite broad coreceptor utilization in transfected
cells, infection of PBMC and MDM was mediated only by
CXCR4 and CCR5, respectively.
We previously showed that primary human adult astrocytes
transduced with CD4 via an adenovirus vector and primary
brain microvascular endothelial cells (BMVECs) that express
low levels of CD4 can support infection by a subset of HIV-1,
HIV-2 and SIV isolates in a CCR5- and CXCR4-independent
manner (Willey et al., 2003). To further investigate whether the
primary virus can use alternative coreceptors for virus entry in
167P.R. Gorry et al. / Virology 362 (2007) 163–178primary human cells, we infected these cells with the primary
virus, as previously described (Willey et al., 2003). No evidence
of infection of CD4-expressing astrocytes or BMVECs by the
primary virus was observed, whereas both cell types supported
productive virus replication by the R5X4 HIV-1 viruses GUN-
1v and HAN-2, the HIV-2 strain TER, and the SIV strain 17Efr
(data not shown). These studies provide further evidence that
infection of primary cells by the virus is unlikely to be mediated
by alternative coreceptors.
Sensitivity to antibody neutralization
We next measured the sensitivity of the primary virus to
neutralization by Env monoclonal antibodies (MAbs) and CD4-
IgG2, as previously described (Trkola et al., 1995) (Fig. 2D).
The neutralizing reagents were human MAbs 2F5 (Muster et al.,
1994; Trkola et al., 1995), 2G12 (Trkola et al., 1995, 1996),
IgG1b12 (Burton et al., 1991, 1994), and the tetrameric CD4-
IgG2 molecule (Allaway et al., 1995). The virus was moderately
sensitive to neutralization by IgG1b12 and CD4-IgG2, but
showed a high level of resistance to neutralization by 2F5 and
2G12, similar to that of 2 other primary viruses studied in
parallel (Fig. 2D and data not shown). Thus, the primary virus is
relatively resistant to neutralization by Env MAbs and CD4-
IgG2, similar to the majority of primary HIV-1 viruses.
Neutralization of heterologous viruses by the subject’s plasma
We determined the ability of the subject’s plasma (obtained
in September 2001; see Supplementary Table 3) to inhibit
infection of PBMC by 6 clade B and 2 clade A HIV-1 viruses as
compared with HIVIG and MAbs IgG1b12, 2F5, and 2G12, as
previously described (Mascola et al., 2002). The IC50s and
IC90s are summarized in Table 1. The subject’s plasma and
HIVIG neutralized infection by 6 diverse clade B and 1 of 2
clade A HIV-1 viruses at plasma dilutions increasing 5-fold
from 1:5 to 1:625, or HIVIG concentrations increasing 10-fold
from 10 μg/ml to 10 mg/ml (Mascola et al., 2002). In contrast,
the MAbs IgG1b12, 2F5 and 2G12, at concentrations increasingTable 1
Virus neutralization studies
Plasma or Ab Clade B HIV-1
SF162 BaL 89.6
Patient a IC50 255 220 261
IC90 42 31 64
b12 b IC50 0.4 1.1 0.3
IC90 2.7 12 5.5
2F5 IC50 2.9 1.1 0.1
IC90 >50 >50 2
2G12 IC50 17 0.1 >50
IC90 >50 10 >50
HIVIG IC50 40 320 13
IC90 680 6590 430
a IC50 and IC90 values of patient plasma neutralization are expressed as the reciproc
of CD8-depleted PBMC. The patient plasma was obtained in September, 2001 (see
b IC50 and IC90 values of Env MAbs and HIVIG are expressed as the concentratio
depleted PBMC.from 0.05 μg/ml to 50 μg/ml, neutralized infection by a subset
of the viruses tested. Compared to plasma and sera from other
HIV-1-infected individuals, the potency and breadth of the
cross-neutralizing activity of the patient’s plasma were in the
top 10% of HIV-1-positive plasma/sera (J. Mascola, unpub-
lished data). Together, these studies suggest that the subject’s
plasma has high levels of cross-neutralizing antibodies.
Characterization of full-length gp160 Env clones
The gp160 coding region of HIV-1 Env was cloned into the
pCR3.1-Uni expression vector. Full-length, functional Env
clones were identified by Western blot analysis of gp120/gp160
in transfected 293T cells and by fusion assays. Four Env clones
that express distinct gp160 and gp120 proteins detected by
Western blot analysis of transfected 293T cells (Fig. 4A) were
sequenced (Fig. 3). Env gp160 amino acid sequences were
uninterrupted in Env clones 6, 16 and 30, but contained a
premature truncation of 4 amino acids in the gp41 cytoplasmic
region in clone 12. The net charge of the V3 variable loops was
+5 in all 4 Env clones. The Env clones contained an asparagine-
rich insertion of 10 amino acids at positions 131 to 140 in the
V1 variable region, which is unique among 207 clade B Envs
screened in the Los Alamos database. Two similar asparagine-
rich insertions of 11 and 6 amino acids were identified at
positions 192 to 202 and 208 to 213, respectively, in the V2
variable region. These insertions result in a net gain of one
potential N-linked glycosylation site in V1, and 3 potential N-
linked glycosylation sites in V2. The total number of potential
N-linked glycosylation sites in gp120 was 20 to 21 compared to
25 in the clade B consensus sequence.
To determine whether the Env clones are representative of
the predominant HIV-1 variants in the viral quasispecies, fusion
and single round entry assays were performed (Figs. 4B, C).
293T cells expressing each Env (Fig. 4A) were fused with Cf2-
Luc cells cotransfected with CD4 and a coreceptor as described
(Gorry et al., 2002a) (Fig. 4B). 293T cells expressing a non-
functional Env or expressing the ADA, HXB2 or 89.6 Env were
used as negative and positive controls, respectively. TheClade A HIV-1
dBR07 aBL01 6101 UG031 RW020
553 90 105 187 32
256 18 27 10 7
0.6 12 >50 >50 >50
22 >50 >50 >50 >50
1.1 3.1 50 9 0.3
>50 >50 >50 >50 4
>50 >50 29 >50 0.6
>50 >50 >50 >50 5
140 685 850 5420 2004
2610 >10000 8700 >10000 6050
al of plasma dilution required to inhibit 50 or 90%, respectively, of viral infection
Supplementary Table 3).
n (μg/ml) required to inhibit 50 or 90%, respectively, of viral infection of CD8-
Fig. 3. Env amino acid sequences. Amino acid sequences were obtained from gp160 env genes cloned from genomic DNA of PBMC infected with the primary virus as
described in Materials and methods. Amino acid alignments of Envs from the patient virus are compared to the clade B consensus sequence. Dots indicate residues
identical to the clade B consensus and dashes indicate gaps.
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cells coexpressing CD4 and CCR2b, CCR3, CCR5, CCR8,
CXCR4, Gpr1, Gpr15, Strl33, Apj or D6. A low level of fusion
was also observed with Cf2-Luc cells expressing CD4 only. We
performed single round entry assays in Cf2th cells expressing
CD4 only or coexpressing CD4 and each of the coreceptors
(Fig. 4C). HIV-1 pseudotyped with Env clones 6 and 30 entered
cells expressing CD4 alone, or coexpressing CD4 and CCR2b,
CCR3, CCR5, CCR8, CXCR4, Gpr1, Gpr15, Strl33, Apj or D6.
In contrast, HIV-1 pseudotyped with Env clones 12 and 16
entered cells coexpressing CD4 and CCR2b, CCR3, CCR5,
CXCR4, Gpr15, Strl33 or Apj, but not cells expressing CD4alone or coexpressing CD4 and CCR8, Gpr1 or D6. The levels
of virus entry mediated by Env clones 12 and 16 were lower
than those mediated by Env clones 6 and 30. Together, these
results demonstrate broad coreceptor usage by 4 Env clones in
fusion and single round entry assays, similar to the pattern of
coreceptor usage of the primary virus isolate (Fig. 1).
Analysis of Env determinants contributing to broad coreceptor
usage
To investigate mechanisms underlying the broad coreceptor
usage of these primary Envs, we analyzed sequences of the V3
Fig. 4. Expression and function of full-length Env clones in cell–cell fusion and infection assays. (A) 293Tcells were cotransfected with 15 μg pCR3.1 Env-expressing
plasmid (Envs 6, 12, 16 and 30) or pSVIII Env-expressing plasmid (ADA, HXB2 and 89.6 Envs) and 2 μg pLTR-Tat. At 72 h post-transfection, cell lysates were
analyzed byWestern blotting using rabbit anti-gp120. The positions of gp160 and gp120 are indicated on the right. (B) 293Teffector cells transfected with Env and Tat
as above were mixed with Cf2-Luc cells transfected with pcDNA3-CD4 only or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR2b, CCR3, CCR5,
CCR8, CXCR4, Gpr1, Gpr15, Strl33, Apj or D6 and incubated at 37 °C for 12 h. Control 293T cells were transfected with ΔKS Env. Mock-transfected Cf2-Luc cells
were transfected with pcDNA3 only. Cell lysates were then prepared and assayed for luciferase activity. (C) HIV-1 luciferase reporter viruses pseudotyped with each
Env were generated and used to infect Cf2th cells transfected with pcDNA3-CD4 only or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR2b, CCR3,
CCR5, CCR8, CXCR4, Gpr1, Gpr15, Strl33, Apj or D6. Control virus was produced by pseudotyping with a non-functional Env (ΔKS Env). Cell lysates were
prepared at 60 h post-infection and assayed for luciferase activity. Data are represented as means from duplicate wells in one experiment. Error bars represent standard
deviations. Results are representative of two independent experiments, each performed in duplicate.
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et al., 2005), and the conserved coreceptor binding site on the
Env core (Rizzuto et al., 1998) to identify amino acid variants
that might influence Env–GPCR interactions. In the V3 region,
patient Envs had Y308, a rare amino acid variant (1.5% of Clade
B Envs, n=23,470) at a position implicated in modulating
resistance to neutralizing antibodies (Zhang et al., 2002) and a
small molecule CCR5 inhibitor (Kuhmann et al., 2004); I317,
an amino acid that contributed to the ability of JR-CSF to use an
N-terminal deletion mutant of CCR5 (Platt et al., 2001); D321
(or E321) and Y330, amino acid changes that affect the overall
charge of V3 and thus may alter interactions with the tyrosine-
sulfated N-terminal region of GPCRs; and T332, a change that
results in the loss of a potential N-linked glycosylation site
relative to the Clade B consensus (Fig. 5A). In the conserved
coreceptor binding site on the Env core, patient Envs had K442
and E444 in the β22 strand near the base of V3, amino acid
variants that could potentially affect electrostatic interactions at
the Env–GPCR interface.
To investigate the contribution of these amino acid variants
to broad coreceptor usage, we used site-directed mutagenesis tochange each of these amino acids to the Clade B consensus
residue in patient Env-30. The parental and mutant Envs were
expressed at similar levels as determined by Western blotting
(Fig. 5B, inset). The ability of Envs to use CCR5, CXCR4, and
alternate coreceptors Gpr1, Gpr15, Strl33, and D6 was analyzed
in cell-to-cell fusion and single round virus entry assays (Fig.
5B and data not shown). The Y308H mutation resulted in an
increased ability to use CCR5, and to a lesser extent CXCR4,
but reduced the capacity of Env-30 to use Gpr1, Gpr15, Strl33,
and D6 (p=0.001, 0.02, 0.02, and 0.04, respectively; Student’s
t test). Additionally, a D321G mutation in Env-30 resulted in an
increased utilization of CCR5, CXCR4, and D6 (p=0.002,
0.049, and 0.006, respectively), but decreased utilization of
Gpr1 and Gpr15 (p=0.006 and 0.048, respectively). In contrast,
a I317F mutation drastically reduced the capacity of Env-30 to
use all coreceptors tested (p<0.01). A K442Q mutation resulted
in a significant decrease in utilization of Gpr1 and Strl33
(p=0.001 and 0.01, respectively) and a minor decrease in
utilization of D6 that did not reach statistical significance, while
a E444R change reduced utilization of CXCR4 and Gpr15
(p<0.01). A Y330H mutation reduced the ability of Env-30 to
Fig. 5. Analysis of Env determinants contributing to broad coreceptor usage (A) V3 and C4 amino acid sequences of the Clade B consensus and patient Env clones
were aligned with Clustal X. Dots represent amino acids identical to the Clade B consensus sequence. Residues important for CCR5 binding (Rizzuto et al., 1998) in
the C4 region are indicated. Amino acid variants analyzed in mutagenesis studies are highlighted in gray. (B) HIV-1 luciferase reporter viruses pseudotyped with each
Env were generated and used to infect Cf2th cells cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR5, CXCR4, Gpr1, Gpr15, Strl33, or D6. Control
virus was produced by pseudotyping with ΔKS Env. Cell lysates were prepared at 60 h post-infection and assayed for luciferase activity. Data were normalized to
parental Env-30 activity and are represented as means from two to three independent experiments, each performed in duplicate. Error bars represent standard error of
the mean. *, p<0.05; **, p<0.01, Student's t test. Inset, 293T cells were cotransfected with 15 μg Env-expressing plasmids and 2 μg pLTR-Tat. At 72 h post-
transfection, cell lysates were analyzed by Western blotting using goat anti-gp120. The positions of gp160 and gp120 are indicated on the left.
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(p=0.01) and had no significant effect on utilization of
Strl33 and D6. A T332N mutation had no significant effect on
entry efficiencies and patterns of coreceptor usage compared
to the parental Env-30 (Fig. 5B). These results suggest that
Y308, D321, and to a lesser extent K442 and E444, contribute
to enhanced gp120 interactions with alternate coreceptors, and
raise the possibility that I317 may be a compensatory change
in patient Env-30.
Molecular modeling of V3 determinants
To elucidate a mechanism for enhanced gp120–coreceptor
interactions in Env-30, we used Swiss PDB viewer to model the
amino acids at positions 308, 317, and 321 on the JRFL gp120-
CD4-X5 CD4i Ab crystal structure (2B4C) (Huang et al., 2005).
The Clade B consensus amino acids at positions 308 and 317 in
the V3 tip region are His and Phe, respectively (Fig. 6A). If the
His at 308 is changed to Tyr, there is an increased potential for
steric clashing when the aromatic ring of Phe is present at
position 317 (Fig. 6B), whereas the smaller side chain of Ile at
this position can accommodate the Tyr at 308 (Fig. 6C). This
finding suggests that the loss of Env function in the I317F
mutant may be due to the lack of a compensatory change atposition 308. Consistent with this prediction, when Y308 is
present in Clade B Envs (n=360), there is a decreased
frequency of amino acids with bulky aromatic side chains
such as Phe and Trp, but an increased frequency of amino acids
with small hydrophobic chains such as Ile and Val at position
317 compared to Clade B Envs (n=23,470) (Table 2), sug-
gesting that covariation may occur at positions 308/317 in vivo.
In Envs with Y308 (n=360 Env sequences from 77 patients),
I317 appeared in 23.9% (n=86 Env sequences from 11 patients)
compared to 4.1% (n=959) of Clade B Envs in the database
(n=23,470) (Table 2). At position 321, Gly may increase the
flexibility of the V3 stem, allowing increased gp120 binding to
GPCRs. An Asp at this position may decrease the flexibility of
the stem, but may also enhance the ability of Env-30 to interact
with some GPCRs that contain positive charges in the N-
terminus, such as Gpr1 and Gpr15. In Envs with Y308, there is
an increased frequency of charged amino acids at position 321
compared to Clade B Envs, raising the possibility that
covariation may also occur at 308/321 (Table 2).
Analysis of Env interactions with attenuated CCR5 coreceptors
GPCRs are 7-transmembrane receptors with an extracellular,
post-translationally modified acidic N-terminal region and three
Fig. 6. Structural modeling of Env V3 determinants contributing to broad coreceptor usage. Swiss PDB viewer was used to model amino acid changes at positions 308,
317, and 321 on the V3 region of the JRFL gp120-CD4-X5 CD4i Ab crystal structure (2B4C) (Huang et al., 2005). JRFLV3 has a single amino acid change relative to
the clade B consensus (N301Q). Red, position 308. Gray, position 317. Cyan, position 321. (A) V3 region of JRFL with H308, F317, and G321. (B) AY308 change in
JRFL results in steric clashing with F317 (dotted lines). (C) Changes Q301N, K305R, S306G, Y308H, F317I, G321D, E322K, I324V, Q328K, H330Y, and N332T
were introduced in JRFL to produce a model of the V3 region of Env-30. Positions Y308, I317, and D321 are indicated.
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contain the major determinants for gp120 binding and core-
ceptor activity (Dragic et al., 1998; Farzan et al., 1998, 1999;
Kuhmann et al., 1997; Lee et al., 1999; Olson et al., 1999; Rabut
et al., 1998; Rucker et al., 1996). The N-terminus of CCR5 has
Tyr sulfation modifications at several sites that are important for
mediating HIVentry (Farzan et al., 1999). To determine whetherTable 2
Frequency and co-variation of unusual amino acid variants in vivo
Position Amino
Acid
Clade B Envs
(n=23470) a
Envs with Y308 (n=360)
Frequency
(%) b
n Frequency
(%)
n Significance c
317 F 78.6 18446 23.6 85 **
W 6.4 1500 0.6 2 **
L 5.1 1194 5.0 18
I 4.1 959 23.9 86 d **
V 2.7 644 45.3 163 **
Y 1.8 411 0.0 0 **
Other 1.3 316 e 1.7 6 f
321 G 79.8 18740 36.7 132 **
E 4.1 970 19.7 71 **
D 2.8 667 7.5 27 **
K 2.0 460 26.9 97 **
R 1.7 389 8.1 29 **
Other 9.6 2244 g 1.1 4 h
a V3 sequence alignment was obtained from the Los Alamos database in
October 2005. Sequence data for Envs with Y308 are from 77 patients.
b Frequency was calculated as [(n/total number of sequences)×100].
c Differences between groups were significant as calculated by Fisher's Exact
Test. **, p<0.005.
d Envs with Y308/I317 are from 11 patients.
e Other indicates amino acids M, S, K, R, C, Q, H, P, T, G, A, D, and E (in
descending order of frequency), or could not be determined.
f Other indicates amino acids M, S, K, E, and P (in descending order of
frequency).
g Other indicates amino acids T, A, Q, N, S, I, and V (in descending order of
frequency), a gap in the alignment, or could not be determined.
h Other indicates amino acid Q or could not be determined.amino acid variants in Env-30 influence interactions with the N-
terminus or ECL2 regions of GPCRs, Cf2 cells expressing CD4
and either wild-type CCR5 (CCR5 (wt)), CCR5 (Y14N) which
has a point mutation in the N-terminal region that changes a Tyr
sulfation site important for mediating HIV-1 entry to an N-
linked glycosylation site (Farzan et al., 1999; Kuhmann et al.,
2000), CCR5 (Δ18) which contains a deletion of the first 18
amino acids of the N-terminal region, or CCR5 (G163R) which
contains a point mutation in the transmembrane region asso-
ciated with a conformational change in ECL2 that is detrimental
to HIV-1 entry (Platt et al., 2001; Siciliano et al., 1999), were
infected with viruses expressing wild-type or mutant Envs.
Primary, macrophage tropic R5 viral isolates use CCR5 (Y14N)
and CCR5 (G163R) at low efficiencies (1.5% and 10–20%
compared to CCR5 (wt), respectively) (Kuhmann et al., 2000;
Platt et al., 2001) and are unable to use CCR5 (Δ18) (Platt et al.,
2005). In contrast to primary R5 Envs, Env-30 used CCR5 (wt)
and CCR5 (G163R) with similar efficiencies (Fig. 7). Y308H
and D321G had reduced utilization of CCR5 (G163R) relative
to CCR5 (wt) compared to Env-30 (Fig. 7), suggesting that
amino acid variants at these positions in patient Env-30 reduce
dependence on the ECL2 region of CCR5. The Y308H,
Y330H, K442Q, and E444R mutants used CCR5 (Y14N) for
entry more efficiently compared to Env-30 (Fig. 7). None of
the Envs could use CCR5 (Δ18) efficiently, consistent with
the critical role of the N-terminal region of GPCRs in binding
and entry (Dragic et al., 1998; Farzan et al., 1998, 1999;
Kuhmann et al., 1997; Rabut et al., 1998; Rucker et al., 1996).
However, the Y308H, D321G, T332N, and E444R mutations
resulted in an increase in the ability of Env-30 to use CCR5
(Δ18), albeit at very low efficiencies. Cell surface expression
levels of CD4 and CCR5 on transfected Cf2th cells were
similar based on staining with CD4-FITC (RPA-T4) and
CCR5-PE (2D7) and FACS analysis (data not shown). Toge-
ther, these results suggest that Y308 and D321 reduce depen-
dence on the ECL2 region of CCR5, while these residues
along with Y330, K442, and E444 increase dependence on the
Fig. 7. Env interactions with attenuated CCR5 coreceptors. HIV-1 luciferase
reporter viruses pseudotyped with each Env were generated and used to infect
Cf2th cells cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR5
(Y14N), CCR5 (Δ18), or CCR5 (G163R). Control virus was produced by
pseudotyping with ΔKS Env. Cell lysates were prepared at 60 h post-infection
and assayed for luciferase activity. Results for each mutant CCR5 were
normalized to levels of luciferase activity in cells expressing CCR5 (wt) for each
Env and are represented as means from two independent experiments, each
performed in duplicate. Error bars represent standard deviations.
172 P.R. Gorry et al. / Virology 362 (2007) 163–178CCR5 N-terminus compared to clade B consensus residues at
these positions.
Discussion
In this study, we isolated and characterized an unusual HIV-1
strain from the blood of an asymptomatic individual who was
heterozygous for the CCR5 Δ32 allele and had reduced levels
of CCR5 expression. The primary virus is dual-tropic and
exhibits unusually broad and efficient utilization of alternative
coreceptors. The repertoire of alternative coreceptors used is
greater than that of any previously described HIV-1 virus, and
more closely resembles that of some SIVand HIV-2 viruses than
that of HIV-1 viruses (Morner et al., 1999; Rucker et al., 1997;
Siciliano et al., 1999). However, in contrast to some SIV and
HIV-2 strains that can infect cells in the absence of CD4
(Reeves et al., 1997, 1999), CCR5- and CXCR4-mediated entry
by the primary virus is strictly CD4-dependent. Previous studies
suggest that expanded use of alternative coreceptors is
associated with rapid HIV-1 disease progression (Bjorndal et
al., 1997; Connor et al., 1997). However, the virus we described
here was isolated from an individual who was asymptomatic for
18 years and had slow disease progression, suggesting that
expanded tropism of HIV-1 can occur in some individuals who
do not have rapid disease progression.
Despite efficient usage of many alternative coreceptors in
transfected cells, the virus exclusively used CXCR4 or CCR5 to
enter primary T cells and monocyte-derived macrophages, res-
pectively. A similar pattern of coreceptor preference for infection
of these primary cells was described for the R5X4 89.6 isolate.
CD4-expressing astrocytes and BMVECS were not infected by
the primary virus, whereas both cell types supported infection by
other unusual HIV-1 and HIV-2 strains. Thus, infection of
primary cells was mediated only by CXCR4 and CCR5.In addition to using CCR2b, CCR3, CCR5, CCR8, CXCR4,
Gpr1, Gpr15, Strl33 and Apj, the patient virus also utilized the
promiscuous CC-chemokine receptor D6 (Nibbs et al., 1997).
Only two previous studies demonstrated HIV-1 entry mediated
via D6 (Choe et al., 1998; Neil et al., 2005). D6 is expressed on
lymphatic endothelial cells, but not on peripheral blood cells or
vascular endothelial cells (Nibbs et al., 2001). In addition to
entry mediated by D6, entry mediated by an endogenous canine
coreceptor was demonstrated, albeit at very low levels. This
property was not observed for over 50 other primary HIV-1
isolates tested in similar assays (data not shown). The identity of
the endogenous canine coreceptor is unknown. However, entry
via this coreceptor was not inhibited by AMD3100, suggesting
it most likely is not CXCR4 (data not shown).
CCR5 cell surface expression levels were very low on the
study subject’s PBMC compared to other CCR5 Δ32 hetero-
zygotes (Cohen et al., 1997; de Roda Husman et al., 1999).
Previous studies demonstrated an increased frequency of R5X4
viruses in CCR5 Δ32 heterozygotes compared to CCR5 wt/wt
individuals (Lathey et al., 2001; Zhang et al., 1998). We
speculate that structural features that enhance interaction of the
primary virus Env described herein with conserved structural
elements in GPCRs may have resulted from adaptive evolution
in the setting of very low levels of CCR5 cell surface expres-
sion. However, validation of this hypothesis would require
longitudinal analysis of Env sequences in the patient’s plasma
and their functional characterization. The primary virus did not
show enhanced sensitivity to antibody neutralization, but the
subject’s plasma had potent neutralizing activity against a wide
variety of HIV-1 strains. This finding raises the possibility that
the Env from the subject’s virus may express epitopes that are
immunogenic and neutralization functional, and may be
responsible for at least some of the cross-reactive neutralizing
activity of his plasma. A better understanding of these epitopes
and their relationship to expanded coreceptor usage may
provide insights relevant for improving HIV-1 immunogenicity
and the elicitation of anti-HIV-1 neutralizing antibodies.
The broad usage of alternate coreceptors suggests that the Env
of this primary virus has unique structural features that enhance
interaction with conserved structural elements in GPCRs. In the
V3 region, patient Envs had the unusual amino acid variants
Y308 (present in 1.5% of Clade B Envs, n=23,470), I317
(4.1%), and D321 (2.8%). Y308H and D321G mutations
increased the capacity of Env-30 to use CCR5 and to a lesser
extent CXCR4, but decreased the utilization of alternate
coreceptors, and an I317F mutation drastically decreased the
capacity of the Env to use any coreceptor. Structural modeling
suggests that a Y308 change in the JRFL crystal structure results
in steric clashing with F317 (the clade B consensus residue),
whereas the smaller side chain of Ile at this position is accom-
modated. Thus, I317 is likely to be a compensatory change for
Y308. D321 may enhance electrostatic interactions with the
positively charged N-terminus of CCR5 and other GPCRs.
These observations, together with evidence for covariation of
amino acids at positions 308/317 and 308/321 in vivo based on
database analysis, suggest that Y308, I317, and D321 may act
cooperatively to enhance Env–GPCR interactions. Env-30 used
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SIVmac251 but reduces entry of primary macrophage tropic
isolates such as ADA and SF162 (Kuhmann et al., 1997), for
entry at levels comparable to those mediated by CCR5 (wt). This
finding is consistent with the promiscuous coreceptor usage of
the patient isolate and Env-30, which resembles that of SIV or
HIV-2 (Edinger et al., 1998; Morner et al., 1999; Reeves et al.,
1997, 1999; Rucker et al., 1997). In addition to enhancing
utilization of alternative coreceptors, Y308 and D321 reduced
the dependence of Env-30 on the ECL2 region of CCR5, while
introducing the clade B consensus residues H308, H330, K442,
and E444 resulted in reduced dependence on the CCR5 N-
terminus. These findings are consistent with a proposedmodel in
which the tip of V3 interacts with ECL2 of GPCRs, while the
more conserved stem and base of V3 interact with the N-terminal
region (Huang et al., 2005; Xiang et al., 2005). K442 and E444 in
the C4 region may work in concert with the changes in V3 by
facilitating interactions with the highly acidic N-terminal region
of CCR5 and other GPCRs. Changes in other regions of Env,
such as those in the V1/V2 region that cooperatively modulate
coreceptor usage with V3 (Nabatov et al., 2004; Pastore et al.,
2006; Sullivan et al., 1993), may further enhance Env–core-
ceptor interactions. Based on our results, we propose that
changes in the V3 region of Env-30 cooperatively enhance
interactions with conserved structural elements in GPCRs, while
changes in the base of V3 and the C4 region may enhance
electrostatic interactions with the N-terminus of GPCRs.
Analysis of patient Env sequences revealed a unique insertion
of 10 amino acids in the V1 region, and two asparagine-rich
insertions of 11 and 6 amino acids in the V2 region. Similar
extensions in the V2 region have been associated with slowHIV-
1 progression or nonprogression (Shioda et al., 1997; Wang et
al., 2000). The V1 insertion in this subject is unusual compared
to other clade B Envs, and the V1/V2 region is longer than that of
other Envs in the database. Changes in Env that reposition the
V1/V2 loops can increase exposure of the coreceptor binding
site (Kolchinsky et al., 2001). These findings raise the possibility
that the unusually long V1/V2 region may reposition the V1/V2
loops, resulting in a conformation that enhances interaction of
gp120 with conserved elements in GPCRs. Conserved elements
in GPCRs important for HIV-1 entry include the tyrosine-rich
sulfated regions in the N-terminus, which are important for
CCR5-mediated HIV-1 entry (Farzan et al., 1999). GPCRs that
mediate entry by the primary virus have many tyrosine residues
within the N-terminus that are probably sulfated in close
proximity, similar to the pattern of sulfated tyrosine residues in
CCR5. Thus, the tyrosine-rich region in the N-terminus is likely
to be one of the conserved elements in GPCRs involved in HIV-1
binding and virus entry.
The subject’s slow disease progression despite harboring a
dual-tropic HIV-1 strain with highly expanded coreceptor usage
may reflect additional viral and/or host factors that can in-
fluence HIV-1 progression. The primary virus had attenuated
replication kinetics in PBMC, CEMx174, and MDM compared
to several laboratory strains (Fig. 3A) and other primary viruses
(Gorry et al., 2001). However, we did not determine whether the
virus studied here was one of the majority sequences present inthe patient. Mutations in the nef gene can cause viral attenuation
and reduced pathogenicity of HIV-1 strains (Deacon et al.,
1995; Kirchhoff et al., 1995). However, we found no deletions
or other obvious defects in nef genes cloned from the primary
virus, which were fully functional for CD4 and MHC-I down-
regulation (K. Agopian and D. Gabuzda, unpublished data).
Further studies are required to determine whether the primary
virus contains any mutations in other viral genes that might be
associated with slow disease progression, and whether it is a
major variant in the patient viral quasispecies in vivo.
In summary, we describe an unusual dual-tropic HIV-1 strain
with highly expanded coreceptor usage isolated from an
asymptomatic individual who was heterozygous for the CCR5
Δ32 allele and had low CCR5 cell surface expression. In this
subject, highly expanded coreceptor usage of HIV-1 occurred
without progression to AIDS, suggesting that R5X4 HIV-1
strains with broadened coreceptor usage can be harbored by
some individuals without rapid disease progression. Our results
suggest that changes in the V3 and C4 regions, possibly a
consequence of adaptive evolution in the setting of very low
levels of CCR5 expression and viral escape from neutralizing
antibodies, act cooperatively to broaden coreceptor usage by
enhancing interactions with conserved structural elements in
GPCRs. These results lead to a better understanding of HIV
Env–GPCR interactions and provide insights that may faci-
litate development of vaccines and therapeutics that target virus
entry.
Materials and methods
Cells
Peripheral blood mononuclear cells were purified from blood
of healthy HIV-1-negative donors by Ficoll-Hypaque density
gradient centrifugation, stimulated with 2 μg/ml phytohemag-
glutinin (PHA) for 3 days and cultured in RPMI 1640 medium
supplemented with 10% (v/v) fetal bovine serum (FBS) and 20
U/ml interleukin-2 (IL-2; Boehringer Mannheim, Germany).
CD8+ T cells were depleted by magnetic separation with anti-
CD8-conjugated magnetic beads (Miltenyi Biotech, Auburn,
CA). Monocyte-derived macrophages were purified from
PBMC by plastic adherence and cultured for 5 days in RPMI
1640 medium supplemented with 10% (v/v) human AB+ serum
and 12.5 ng/ml M-CSF. Cf2-Luc cells (Etemad-Moghadam et
al., 2000), derived from the Cf2th canine thymocyte cell line
(Choe et al., 1996), stably express the luciferase gene under the
control of the HIV-1 LTR. Cf2-Luc cells were cultured in
DMEM medium supplemented with 10% (v/v) FBS, and
0.7 mg/ml G418. Cf2th cells were cultured in the same medium
without G418. CEMx174 cells were cultured in RPMI 1640
medium supplemented with 10% (v/v) FBS.
Isolation of HIV-1
HIV-1 was isolated from patient PBMC by coculture with
CD8-depleted donor PBMC as described previously (Gorry
et al., 2001). Briefly, 2×106 patient cells were added to
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incubated at 37 °C for 1 h, and then cultured in 10 ml growth
media containing 20 U/ml IL-2. Fifty percent media changes
were performed twice weekly. Five million fresh PHA-activated,
CD8-depleted PBMC from a different donor were added at every
second media change. Supernatants were tested for reverse
transcriptase (RT) activity using [3H]dTTP incorporation.
Supernatants testing positive for RT were filtered through
0.45 μm filters and stored at −80 °C.
Coreceptor usage
To determine coreceptor usage by the patient HIV-1 isolate,
Cf2-Luc cells were cotransfected with 10 μg of plasmid
pcDNA3-CD4 and 20 μg of plasmid pcDNA3 containing
CCR2b, CCR3, CCR5, CCR8, CXCR4, CX3CR1, Gpr1,
Gpr15, Strl33, Apj, CX3CR1, Rdc1, CCR7, CXCR1, CXCR2,
CXCR3, C5aRC9, D2DrsC9, DARC, D6 or FMLP-R using the
calcium phosphate method, and infected 48 h later by incubation
with 10,000 3H cpmRTunits of HIV-1 in the presence of 2 μg/ml
polybrene as described previously (Gorry et al., 2001). Mock-
infected cells were treated with culture medium. Cf2-Luc cells
mock-transfected or transfected with pcDNA3-CD4 alone were
used as negative controls. After overnight infection, virus was
removed and the cells were cultured for an additional 48 h prior
to lysis in 200 μl cell lysis buffer. Cell lysates were cleared by
centrifugation, and assayed for luciferase activity according to
the manufacturers’ protocol (Promega).
HIV-1 replication kinetics
Five million PHA-activated PBMC were infected by
incubation with 50,000 3H cpm RT units of virus supernatant
in a volume of 2 ml for 3 h at 37 °C. Virus was then removed
and PBMC were washed 3 times with PBS and cultured in
media containing 20 U/ml IL-2 for 28 days. Monocyte-derived
macrophages were isolated from PBMC by plastic adherence
and allowed to mature for 5 days prior to seeding in 6-well
tissue culture plates at approximately 90% confluence. Virus
equivalent to 50,000 3H cpm RT units in a volume of 2 ml was
allowed to adsorb to the cell monolayers for 3 h at 37 °C. Virus
was then removed and cells were rinsed 3 times with PBS prior
to addition of 2 ml culture medium. Five million CEMx174
cells were infected by incubation with 50,000 3H cpm RT units
of virus supernatant in a volume of 2 ml for 3 h at 37 °C. Virus
was then removed and cells were washed 3 times with PBS and
cultured for 28 days. Fifty percent media changes were
performed twice weekly and supernatants were tested for
HIV-1 by RT assays.
Virus inhibition studies
The effects of the coreceptor inhibitors TAK-779 (Baba et
al., 1999) and AMD-3100 (Donzella et al., 1998; Schols et al.,
1997) on virus replication in PBMC were assayed as described
elsewhere (Gorry et al., 2002a; Trkola et al., 1998). Briefly,
PBMC were incubated for 30 min with a range of concentra-tions of each inhibitor (0.01 to 100 μM) prior to infection with
the patient virus isolate. Virus replication was measured by
production of HIV-1 p24 antigen in culture supernatants for
14 days (Trkola et al., 1995). The production of p24 antigen in
the presence of an inhibitor was expressed as a percentage of the
amount produced in control cultures containing no inhibitor. For
virus inhibition studies in MDM, cells were preincubated with
100 nM TAK-779 or 1.2 μM AMD3100 for 1 h prior to
infection with HIV-1 isolates containing the same concentration
of inhibitor, as described previously (Gorry et al., 2001).
Infected cells were cultured for 21 days in the presence of each
inhibitor. Fifty percent media changes were performed weekly
and supernatants were tested for HIV-1 by RT assays.
Neutralization assays
Human monoclonal antibodies (MAb) against HIV-1 gp120
(IgG1b12 and 2G12) and gp41 (2F5), the tetrameric CD4-
immunoglobulin (CD4-IgG2) molecule, and purified polyclonal
anti-HIV immunoglobulin (HIVIG) have been described
previously (Allaway et al., 1995; Burton et al., 1991, 1994;
Mascola et al., 2002; Muster et al., 1994; Trkola et al., 1995,
1996). Neutralization of replication of the patient virus isolate in
PBMC was assessed as described previously (Trkola et al.,
1995). Briefly, virus was incubated for 30 min with a range of
concentrations of each Mab or CD4-Ig2 (0.01 to 100 μg/ml)
prior to infection. Virus replication and calculation of percent
neutralization were measured as described above. Neutraliza-
tion of heterologous viruses by the subject’s plasma was
assessed as described by Mascola et al. (2002).
PCR amplification, HIV-1 Env cloning and sequence analysis
Genomic DNAwas extracted from PBMC infected with the
patient virus isolate using the DNeasy DNA extraction kit
(Qiagen). Full-length Env genes were amplified from genomic
DNA with RTth XL polymerase and nested primers using hot
start AmpliWax PCR Gem 50 (Applied Biosystems), as
described previously (Gorry et al., 2002a). Env PCR-product
DNAwas gel purified and cloned into pCR3.1-Uni (Invitrogen).
Functional full-length Env clones were identified by Western
blot analysis of gp120/gp160 in transfected 293T cells and by
fusion assays. Env clones were sequenced using a model 3100
Genetic Analyzer (Applied Biosystems). Y308H, I317F,
D321G, Y330H, T332N, K442Q, and E444R mutant Env
plasmids were created by PCR-based mutagenesis and changes
were verified by DNA sequencing.
Western blot analysis
For analysis of Env expression, 293T cells were transfected
with 15 μg of different pCR3.1 Env clones, or 15 μg pSVIII
plasmid expressing ADA, HXB2 or 89.6 Env plus 2 μg pLTR-
Tat plasmid. At 72 h after transfection, cells were rinsed twice in
PBS and resuspended in 400 μl of ice-cold lysis buffer for
20 min, followed by centrifugation at 15,300×g for 10 min to
remove cellular debris. Cell lysates were separated in 8.5%
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anti-gp120 polyclonal antisera (American Biotechnologies Inc.)
or goat anti-gp120 polyclonal antisera (NIH AIDS Research and
Reference Reagent program). Env proteins were visualized
using horseradish peroxidase-conjugated anti-rabbit or anti-goat
immunoglobulin G antibodies and enhanced chemilumines-
cence (Perkin Elmer).
Fusion assays
293T cells (1×105) cotransfected with 15 μg Env-expressing
plasmid and 2 μg pLTR-Tat were mixed with Cf2-Luc cells
(1×106) that had been cotransfected with 10 μg pcDNA3-CD4
and 20 μg pcDNA3 expressing an alternative coreceptor as
indicated, then incubated at 37 °C in 0.75 ml culture medium.
Mock-transfected Cf2-Luc cells were transfected with pLTR-
Tat only. Control 293T cells were cotransfected with pLTR-Tat
and a non-functional Env (pSVIII-ΔKS Env). Twelve hours
later, cells were harvested and assayed for luciferase activity as
described above.
Single round entry assays
An Env complementation assay was used to quantitate HIV-1
entry as described (Choe et al., 1996). Briefly, recombinant HIV-
1 luciferase reporter viruses were generated by cotransfection of
293T cells by the calcium phosphate method with 16 μg of
pNL4-3env− Luc, which contains an HIV-1 provirus with a
deletion in the env gene and a replacement of the nef gene with a
luciferase gene, and 6 μg of pCR3.1Env or pSVIIIEnv plasmid.
Cf2th cells intended for use as target cells were cotransfected
with 10 μg pcDNA3-CD4 and 20 μg pcDNA3 expressing an
alternative coreceptor as indicated. Plasmids expressing CCR5
(Y14N), CCR5 (Δ18), and CCR5 (G163R) were kindly
provided by D. Kabat. Approximately 48 h after transfection,
these cells were infected by incubation with 20,000 3H cpm RT
units of recombinant luciferase reporter viruses. Reporter viruses
pseudotyped with a non-functional Env (pSVIII-ΔKSenv) were
used as negative controls. Sixty hours later, cells were harvested
and assayed for luciferase activity.
Nucleotide sequence accession numbers
Nucleotide sequences were submitted to GenBank (acces-
sion numbers AY624304 through AY624307).
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